Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry.
A distinctive feature of HCV is that its life cycle depends on lipoprotein metabolism. Viral morphogenesis and secretion follow the very low-density lipoprotein (VLDL) biogenesis pathway and, consequently, infectious HCV in the serum is associated with triglyceride-rich lipoproteins (TRL). Lipoprote...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1f98f4b688604b5890b734ac5cde75fd |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1f98f4b688604b5890b734ac5cde75fd |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1f98f4b688604b5890b734ac5cde75fd2021-11-18T07:35:56ZLipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry.1932-620310.1371/journal.pone.0026637https://doaj.org/article/1f98f4b688604b5890b734ac5cde75fd2011-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22039521/?tool=EBIhttps://doaj.org/toc/1932-6203A distinctive feature of HCV is that its life cycle depends on lipoprotein metabolism. Viral morphogenesis and secretion follow the very low-density lipoprotein (VLDL) biogenesis pathway and, consequently, infectious HCV in the serum is associated with triglyceride-rich lipoproteins (TRL). Lipoprotein lipase (LPL) hydrolyzes TRL within chylomicrons and VLDL but, independently of its catalytic activity, it has a bridging activity, mediating the hepatic uptake of chylomicrons and VLDL remnants. We previously showed that exogenously added LPL increases HCV binding to hepatoma cells by acting as a bridge between virus-associated lipoproteins and cell surface heparan sulfate, while simultaneously decreasing infection levels. We show here that LPL efficiently inhibits cell infection with two HCV strains produced in hepatoma cells or in primary human hepatocytes transplanted into uPA-SCID mice with fully functional human ApoB-lipoprotein profiles. Viruses produced in vitro or in vivo were separated on iodixanol gradients into low and higher density populations, and the infection of Huh 7.5 cells by both virus populations was inhibited by LPL. The effect of LPL depended on its enzymatic activity. However, the lipase inhibitor tetrahydrolipstatin restored only a minor part of HCV infectivity, suggesting an important role of the LPL bridging function in the inhibition of infection. We followed HCV cell entry by immunoelectron microscopy with anti-envelope and anti-core antibodies. These analyses demonstrated the internalization of virus particles into hepatoma cells and their presence in intracellular vesicles and associated with lipid droplets. In the presence of LPL, HCV was retained at the cell surface. We conclude that LPL efficiently inhibits HCV infection by acting on TRL associated with HCV particles through mechanisms involving its lipolytic function, but mostly its bridging function. These mechanisms lead to immobilization of the virus at the cell surface. HCV-associated lipoproteins may therefore be a promising target for the development of new therapeutic approaches.Patrick MaillardMarine WalicPhilip MeulemanFarzin RoohvandThierry HubyWilfried Le GoffGeert Leroux-RoelsEve-Isabelle PécheurAgata BudkowskaPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 10, p e26637 (2011) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Patrick Maillard Marine Walic Philip Meuleman Farzin Roohvand Thierry Huby Wilfried Le Goff Geert Leroux-Roels Eve-Isabelle Pécheur Agata Budkowska Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. |
| description |
A distinctive feature of HCV is that its life cycle depends on lipoprotein metabolism. Viral morphogenesis and secretion follow the very low-density lipoprotein (VLDL) biogenesis pathway and, consequently, infectious HCV in the serum is associated with triglyceride-rich lipoproteins (TRL). Lipoprotein lipase (LPL) hydrolyzes TRL within chylomicrons and VLDL but, independently of its catalytic activity, it has a bridging activity, mediating the hepatic uptake of chylomicrons and VLDL remnants. We previously showed that exogenously added LPL increases HCV binding to hepatoma cells by acting as a bridge between virus-associated lipoproteins and cell surface heparan sulfate, while simultaneously decreasing infection levels. We show here that LPL efficiently inhibits cell infection with two HCV strains produced in hepatoma cells or in primary human hepatocytes transplanted into uPA-SCID mice with fully functional human ApoB-lipoprotein profiles. Viruses produced in vitro or in vivo were separated on iodixanol gradients into low and higher density populations, and the infection of Huh 7.5 cells by both virus populations was inhibited by LPL. The effect of LPL depended on its enzymatic activity. However, the lipase inhibitor tetrahydrolipstatin restored only a minor part of HCV infectivity, suggesting an important role of the LPL bridging function in the inhibition of infection. We followed HCV cell entry by immunoelectron microscopy with anti-envelope and anti-core antibodies. These analyses demonstrated the internalization of virus particles into hepatoma cells and their presence in intracellular vesicles and associated with lipid droplets. In the presence of LPL, HCV was retained at the cell surface. We conclude that LPL efficiently inhibits HCV infection by acting on TRL associated with HCV particles through mechanisms involving its lipolytic function, but mostly its bridging function. These mechanisms lead to immobilization of the virus at the cell surface. HCV-associated lipoproteins may therefore be a promising target for the development of new therapeutic approaches. |
| format |
article |
| author |
Patrick Maillard Marine Walic Philip Meuleman Farzin Roohvand Thierry Huby Wilfried Le Goff Geert Leroux-Roels Eve-Isabelle Pécheur Agata Budkowska |
| author_facet |
Patrick Maillard Marine Walic Philip Meuleman Farzin Roohvand Thierry Huby Wilfried Le Goff Geert Leroux-Roels Eve-Isabelle Pécheur Agata Budkowska |
| author_sort |
Patrick Maillard |
| title |
Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. |
| title_short |
Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. |
| title_full |
Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. |
| title_fullStr |
Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. |
| title_full_unstemmed |
Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. |
| title_sort |
lipoprotein lipase inhibits hepatitis c virus (hcv) infection by blocking virus cell entry. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2011 |
| url |
https://doaj.org/article/1f98f4b688604b5890b734ac5cde75fd |
| work_keys_str_mv |
AT patrickmaillard lipoproteinlipaseinhibitshepatitiscvirushcvinfectionbyblockingviruscellentry AT marinewalic lipoproteinlipaseinhibitshepatitiscvirushcvinfectionbyblockingviruscellentry AT philipmeuleman lipoproteinlipaseinhibitshepatitiscvirushcvinfectionbyblockingviruscellentry AT farzinroohvand lipoproteinlipaseinhibitshepatitiscvirushcvinfectionbyblockingviruscellentry AT thierryhuby lipoproteinlipaseinhibitshepatitiscvirushcvinfectionbyblockingviruscellentry AT wilfriedlegoff lipoproteinlipaseinhibitshepatitiscvirushcvinfectionbyblockingviruscellentry AT geertlerouxroels lipoproteinlipaseinhibitshepatitiscvirushcvinfectionbyblockingviruscellentry AT eveisabellepecheur lipoproteinlipaseinhibitshepatitiscvirushcvinfectionbyblockingviruscellentry AT agatabudkowska lipoproteinlipaseinhibitshepatitiscvirushcvinfectionbyblockingviruscellentry |
| _version_ |
1718423208428830720 |